Incyte (INCY) announced the immediate retirement of CEO Herve Hoppenot, with Bill Meury, former CEO of Anthos and Karuna (KRTX), stepping in as his successor, RBC Capital tells investors in a research note. Investors may speculate that Incyte could become an M&A target given Meury’s history of high-profile biotech sales, though Incyte’s commercial-stage profile and looming Jakafi patent cliff, which could cut earnings by 76% by decade’s end, may limit that potential, but Meury’s experience is seen as a positive for Incyte’s strategic direction, the firm says. RBC Capital has a Sector Perform rating and $67 price target on Incyte shares.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte CEO Herve Hoppenot to retire, Bill Meury to succeed
- Monjuvi’s Strategic Advantage in Follicular Lymphoma: Analyst Recommends Buy Amid FDA Approval and Projected Revenue Growth
- J&J’s ‘968 delay has mixed readthroughs for Incyte’s ‘989, says RBC
- Sutro, Sarepta, Incyte, Signet, Wix: Trending by Analysts
- Incyte announces FDA extends review period for Opzelura sNDA